Loading
Latest filing published 23 Sept 2026 for 바이오톡스텍. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
강종구, listed as chief executive, appears in our data through filings on 바이오톡스텍 shares, published by DART (FSS). We count 27 filings; the first trade dates from 28 March 2022 and the latest from 23 September 2026.
On the market, this insider has only ever bought: 13 purchases. No amount is published for 13 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 6 purchases and no sales.
The 11 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 23 September 2026, reports a transaction in 바이오톡스텍. The last purchase on record was published on 1 September 2026, which is 47 days ago. Filings reach the DART (FSS) feed a median of 2 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 27 declarations